Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials at 52 Weeks

被引：0
|
作者：
Paller, Amy [1 ]
Mendes-Bastos, Pedro [2 ]
Eichenfield, Lawrence [3 ,4 ,5 ]
Soong, Weily [6 ]
Lio, Peter [7 ]
Prajapati, Vimal [8 ,9 ,10 ]
Platt, Andrew [11 ]
Liu, John [11 ]
Ladizinski, Barry [11 ]
Thyssen, Jacob
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA
[2] Hosp CUF Descobertas, Dermatol Ctr, Lisbon, Portugal
[3] Univ Calif San Diego, Sch Med, Rady Childrens Hosp, Div Pediat & Adolescent Dermatol, San Diego, CA USA
[4] Univ Calif San Diego, Sch Med, Dept Dermatol, San Diego, CA USA
[5] Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA USA
[6] AllerVie HealthAlabama Allergy & Asthma Ctr & Cli, Birmingham, AL USA
[7] Med Dermatol Associates Chicago, Chicago, IL USA
[8] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[9] Univ Calgary, Sect Community Pediat, Dept Pediat, Calgary, AB, Canada
[10] Univ Calgary, Sect Pediat Rheumatol, Calgary, AB, Canada
[11] AbbVie Inc, N Chicago, IL USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
43049
引用
收藏
页码：AB157 / AB157
页数：1
相关论文
共 50 条
  • [31] Characterization of haematological and transaminase laboratory findings associated with upadacitinib use in moderate-to-severe atopic dermatitis: results of two phase III Trials (Measure Up 1 and 2)
    Silverberg, J. I.
    Gooderham, M. J.
    de Bruin-Weller, M. S.
    Papp, K. A.
    Aoki, V.
    Paller, A. S.
    Ofori, S.
    Tenorio, A. R.
    Liu, Y.
    Liu, J.
    Chovatiya, Raj
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E168 - E169
  • [32] Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Prajapati, Vimal H.
    Rosmarin, David
    Shumack, Stephen
    Calimlim, Brian M.
    Takemoto, Shunya
    Hu, Xiaofei
    Ladizinski, Barry
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E81
  • [33] Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis
    Qiu, Mei
    Duan, Xue-Yan
    Yin, Dao-Gen
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (01) : E24 - E26
  • [34] Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    Costanzo, A.
    De Bruin-Weller, M.
    Barbarot, S.
    Prajapati, V. H.
    Lio, P.
    Hu, X.
    Wu, T.
    Liu, J.
    Ladizinski, B.
    Chu, A. D.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E123
  • [35] ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES
    Prajapatil, Vimal
    Simpson, Eric L.
    Thyssen, Jacob P.
    Chovatiya, Raj
    Lane, Michael
    Teixeira, Henrique
    Calimlim, Brian
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 33 - 33
  • [36] Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks
    Paller, Amy S.
    Mendes-Bastos, Pedro
    Siegfried, Elaine
    Eichenfield, Lawrence F.
    Soong, Weily
    Prajapati, Vimal H.
    Lio, Peter
    Simpson, Eric L.
    Raymundo, Eliza M.
    Suravaram, Smitha
    Hu, Xiaofei
    Yang, Yang
    Huang, Xiaohong
    Calimlim, Brian M.
    Platt, Andrew M.
    Su, John C.
    Zheng, Min
    Yamamoto-Hanada, Kiwako
    Teixeira, Henrique D.
    Irvine, Alan D.
    JAMA DERMATOLOGY, 2024, 160 (12) : 1304 - 1313
  • [37] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Reich, Kristian
    Teixeira, Henrique D.
    de Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Werfel, Thomas
    Zeng, Jiewei
    Huang, Xiaohong
    Hu, Xiaofei
    Hendrickson, Barbara A.
    Ladizinski, Barry
    Chu, Alvina D.
    Silverberg, Jonathan I.
    LANCET, 2021, 397 (10290): : 2169 - 2181
  • [38] DISCONTINUATION OF TOPICAL CORTICOSTEROIDS IN UPADACITINIB-TREATED PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS FROM THE AD UP PHASE 3 TRIAL
    Reich, Kristian
    Boguniewicz, Mark
    Kabashima, Kenji
    Barbarot, Sebastien
    Girolomoni, Giampiero
    Mendes-Bastos, Pedro
    Gamelli, Amy
    Liu, Yingyi
    Teixeira, Henrique
    Armstrong, April
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 61 - 61
  • [39] Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials
    Zeng, Linxi
    Feng, Sen
    Yao, Lulu
    Wang, Bin
    Zhang, Guoqiang
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2023, 40 (06): : 734 - 740
  • [40] Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
    Zirwas, Matthew J.
    Boguniewicz, Mark
    Rosmarin, David
    Fuxench, Zelma Chiesa
    Warren, Richard B.
    Torres, Tiago
    de Bruin-Weller, Marjolein
    Dawson, Zach
    Atwater, Amber Reck
    Elmaraghy, Hany
    Pierce, Evangeline
    Bardolet, Laia
    Zhong, Jinglin
    Armstrong, April W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 54 - 56
12345